1 citations
,
November 2024 in “Neuro-Oncology” Temozolomide can cause severe bone marrow suppression, leading to life-threatening complications.
23 citations
,
October 2015 in “Plastic and reconstructive surgery/PSEF CD journals” Radiesse is a versatile facial injectable used for cosmetic improvements and long-term collagen production, with careful dosing needed to prevent complications.
6 citations
,
May 2013 in “Journal of Clinical Oncology” Combining Ficlatuzumab and Gefitinib can cause severe hair loss.
150 citations
,
March 1995 in “Annals of Oncology” Palliative chemotherapy is cost-effective for advanced gastric and colorectal cancer but not clearly for pancreatic-biliary cancer.
February 2026 in “Scientific Reports” The gel is safe and effective for treating oral mucositis from chemotherapy and radiation.
1 citations
,
November 2024 in “Blood” PI3Kδ inhibition may effectively treat cutaneous chronic graft-versus-host disease.
41 citations
,
December 2008 in “Journal of the American Academy of Dermatology” Oral valganciclovir improved a patient's skin condition caused by immunosuppression.
June 2025 in “BMJ Case Reports” Axitinib treatment turned a man's grey hair back to black.
April 2016 in “The journal of investigative dermatology/Journal of investigative dermatology” Topical gabapentin was safe and effective for treating scalp symptoms and promoting hair regrowth in cicatricial alopecias.
2 citations
,
February 2023 in “Research Square (Research Square)” The scaffold effectively prevents melanoma relapse and aids wound healing.
1 citations
,
July 2018 in “Dermatologic Surgery” Different tumor cells in one basal cell carcinoma can cause mixed treatment responses, suggesting personalized treatment is needed.
April 2018 in “Dermatologic Surgery”
78 citations
,
March 2004 in “Annals of Oncology” The treatment combining docetaxel, cisplatin, and 5-FU is feasible and effective for advanced head and neck cancer.
2 citations
,
May 2016 in “Journal of Clinical Oncology” Topical calcitriol may reduce hair loss from chemotherapy at higher doses.
October 2018 in “Annals of oncology” Topical calcitriol (BPM31543) is safe for preventing hair loss from chemotherapy and shows some effectiveness.
1 citations
,
July 2025 in “Clinical and Experimental Dermatology” Deucravacitinib led to full hair regrowth in a severe alopecia areata patient.
January 2016 in “Refubium (Universitätsbibliothek der Freien Universität Berlin)” CAP7.1 is generally safe at 200 mg/m²/day, but can cause fatigue, nausea, hair loss, fever, and blood-related issues.
5 citations
,
January 2012 in “JBI Library of Systematic Reviews” Avemar may help in cancer treatment, but its effectiveness isn't proven yet.
9 citations
,
November 2023 in “Supportive Care in Cancer” 1 citations
,
January 2026 in “International Journal of Dermatology” Amivantamab can cause severe skin eruptions and scarring, requiring drug discontinuation and early treatment.
August 1993 in “Journal of dermatological science” March 2021 in “Arrow - TU Dublin (Technological University Dublin)” The folate-cyclodextrin conjugate targets cancer cells more precisely, potentially reducing chemotherapy side effects.
December 2025 in “Dermatology Reports” Topical ruxolitinib quickly improves non-segmental vitiligo.
May 2025 in “JEADV Clinical Practice” The cream effectively treats scalp psoriasis, improving symptoms and quality of life, with high patient satisfaction.
March 2024 in “Clinical, cosmetic and investigational dermatology” Tofacitinib successfully treated vitiligo in a patient with lupus without side effects.
January 2021 in “Mastology” Scalp cooling therapy helped over 80% of women keep at least half their hair during chemotherapy.
2 citations
,
May 2008 in “Journal of Clinical Oncology” AZD6244 treatment causes skin aging effects by depleting skin stem cells.
33 citations
,
January 2018 in “Blood” Ruxolitinib helps protect skin stem cells and keeps skin healthy in mice with skin GVHD.
294 citations
,
March 2016 in “European journal of cancer” Neoadjuvant chemotherapy followed by surgery leads to fewer severe complications and better quality of life than immediate surgery in advanced ovarian cancer patients with high tumor load.
1 citations
,
January 2017 in “International journal of trichology” Diphenylcyclopropenone (DPCP) effectively treated both alopecia areata and verruca vulgaris.